Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354844 | 1.00 | MEN1 (0.48) | MEN1KMT2AATMMAPK1OPRM1 | |
| SCHEMBL23943826 | 0.87 | MEN1 (0.49) | MEN1KMT2AATMMAPK1OPRM1 | |
| SCHEMBL25264500 | 0.87 | MEN1 (0.49) | MEN1KMT2AATMMAPK1OPRM1 | |
| SCHEMBL25353543 | 0.85 | PDE10A (0.41) | MEN1KMT2AATMDRD2PDE10A | |
| SCHEMBL30453579 | 0.84 | HCRTR1 (0.41) | MEN1KMT2AATMMAPK1DRD2 | |
| SCHEMBL25355121 | 0.84 | HCRTR1 (0.41) | MEN1KMT2AATMMAPK1DRD2 | |
| SCHEMBL25193082 | 0.84 | MEN1 (0.48) | MEN1KMT2AATMMAPK1OPRM1 | |
| SCHEMBL23944140 | 0.84 | MEN1 (0.48) | MEN1KMT2AATMMAPK1OPRM1 | |
| SCHEMBL25285176 | 0.83 | DRD4 (0.41) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL25353198 | 0.83 | DRD4 (0.41) | DRD2ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | MEN1 762/4885KMT2A 1106/4885ATM 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.